You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》传亚盛医药已通过上市聆讯最快本月启动招股
阿思达克 06-18 10:18

据市场消息称,专注全球创新的1类新药研发企业亚盛医药已於日前通过港交所(00388.HK)上市聆讯,最快於本月底展开上市前推介及启动公开招股,拟於7月挂牌上市,有望成为原创小分子1类新药第一股。是次上市联席保荐人为美银美林及花旗。

据亚盛医药上市文件,该公司旨在解决尚未满足、无药可医的临床需求,现已有8款原创1类新药进入临床阶段,目前正在中国、美国及澳洲进行20项I期或II期临床试验。其产品管线包括靶向细胞凋亡路径关键蛋白的抑制剂、新一代酪氨酸激(酉每)抑制剂等。公司核心产品HQP1351为针对格列卫耐药的第三代产品,已进入关键注册临床II期试验,有望通过临床二期结果即申请上市。(el/ca) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account